Loading...
XNAS
BLFS
Market cap1.33bUSD
Jul 09, Last price  
28.23USD
1D
3.82%
1Q
43.01%
Jan 2017
1,653.09%
Name

BioLife Solutions Inc

Chart & Performance

D1W1MN
XNAS:BLFS chart
P/E
P/S
14.34
EPS
Div Yield, %
Shrs. gr., 5y
12.24%
Rev. gr., 5y
14.88%
Revenues
96m
+16.97%
603,219972,2621,322,4971,581,6002,081,5652,758,7295,662,9908,949,4016,190,6986,448,9108,227,00011,022,00019,742,00027,371,00048,087,000119,156,00076,239,00075,855,00082,254,00096,214,000
Net income
-12m
L-39.90%
-1,134,018-2,851,774-2,775,117-2,768,352-1,983,630-1,956,639-1,659,586-1,084,160-3,217,750-4,213,936-6,875,000-2,515,0003,266,000-1,657,0002,667,000-8,908,000-139,805,000-66,427,000-20,184,000-12,130,000
CFO
20m
+138.58%
-712,196-2,708,979-2,113,418-2,413,642-1,252,526-989,917854,934146,007-3,162,316-4,973,861-4,327,000605,0002,348,0001,213,0006,515,000-4,836,000-8,489,000-12,498,0008,431,00020,115,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.
IPO date
Nov 22, 1989
Employees
466
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT